The Improvement in Symptoms After Sublingual Immunotherapy for Japanese Cedar Pollinosis Coincided With the Reduction in Nasal Metachromatic and Eosinophilic Cells
Restricted accessResearch articleFirst published online July, 2025
The Improvement in Symptoms After Sublingual Immunotherapy for Japanese Cedar Pollinosis Coincided With the Reduction in Nasal Metachromatic and Eosinophilic Cells
Previously, it was reported that droplet SLIT in Japanese cedar pollinosis reduced metachromatic cell and eosinophil counts in nasal swabs along with symptom improvement. In this study, it was confirmed that SLIT using tablets also reduces the number of these cells along with symptom improvement, and examined the time course of these effects.
Methods
One hundred twenty-one visits of 57 subjects treated with SLIT occurred in our clinic between January 16 and April 8, 2023 (Jc pollen season). The 57 patients had been receiving SLIT for 0.16 to 7.8 yr, and symptoms were assessed using a self-reported questionnaire. Nasal swab cytology was used to compare the reduction in Mc, eosinophil and neutrophil numbers with that of non-SLIT 110 subjects. We then investigated the timelines of the decrease in Mc and eosinophils and their relationship to symptoms.
Results
C Subjects who received SLIT had significantly reduced moderate to most severe symptoms compared to non-SLIT subjects over the Jc pollen season. There was symptom improvement for subjects with ≤2 yr SLIT treatment, but more improvement after >2 yr of SLIT treatment. Mc and eosinophil numbers in nasal swabs of SLIT subjects were significantly lower than in non-SLIT subjects. Moreover, levels of eosinophilia decreased within 2 yr of SLIT treatment, but further decreased with >2 yr of SLIT. Mc numbers in subjects with >2 years of SLIT were significantly lower than in non-SLIT subjects. There was no significant difference in neutrophil numbers in nasal swabs between non-SLIT and SLIT subjects.
Conclusion
SLIT administered by tablet was effective in improving symptoms within 2 yr, and further improved after 2 yr. The eosinophil counts also decreased within 2 yr, and further decreased over 2 yr. The Mc count significantly decreased only after 2 yr of SLIT treatment.
MuraroARobertsGHalkenS, et al.EAACI Guidelines on allergen immunotherapy: Executive statement. Allergy. 2018;73(4):739‐743.
2.
HalkenSLarenas-LinnemannDRobertsG, et al.EAACI Guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017;28(8):728‐745.
3.
RobertsGPfaarOAkdisCA, et al.EAACI Guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765‐798.
AminHSLissGMBernsteinDI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006;117(1):169‐175.
6.
OkuboKGotohM. Sublingual immunotherapy for Japanese cedar pollinosis. Allergol Int. 2009;58(2):149‐154.
7.
OkamotoYOkuboKYonekuraS, et al.Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 2015;166(3):177‐188.
8.
GotohMYonekuraSImaiT, et al.Long-term efficacy and dose-finding trial of Japanese cedar pollen sublingual immunotherapy tablet. J Allergy Clin Immunol Pract. 2019;7(4):1287‐1197.
9.
YonekuraSGotohMKanekoS, et al.Treatment duration-dependent efficacy of Japanese cedar pollen sublingual immunotherapy: Evaluation of a phase II/III trial over three pollen dispersal seasons. Allergol Int. 2019;68(4):494‐505.
10.
DurhamSREmmingerWKappA, et al.Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125(1):131‐138.
11.
CreticosPSEschRECourouxP, et al.Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133(3):751‐758.
12.
BiedermannTKunaPPanznerP, et al.The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2019;143(3):1058‐1066.
13.
PfaarOBachertCKunaP, et al.Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. J Allergy Clin Immunol. 2019;143(3):970‐977.
14.
MoingeonPBatardTFadelR, et al.Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006;61(2):151‐165.
15.
ScaddingGWShamjiMHJacobsonMR, et al.Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010;40(4):598‐606.
16.
Suárez-FueyoARamosTGalánA, et al.Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol. 2014;133(1):130‐138.
17.
OtsukaHDenburgJDolovichJ, et al.Heterogeneity of metachromatic cells in human nose: Significance of mucosal mast cells. J Allergy Clin Immunol. 1985;76(5):695‐702.
18.
BentleyAMJacobsonMRCumberworthV, et al.Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol. 1992;89(4):877‐883.
19.
JuliussonSPipkornUKarlssonG, et al.Mast cells and eosinophils in the allergic mucosal response to allergen challenge: Changes in distribution and signs of activation in relation to symptoms. J Allergy Clin Immunol. 1992;90(6 Pt 1):898‐909.
20.
KawaboriSKanaiN. Distribution of MCT and MCTC in nasal mucosae relationship with formalin-sensitive mast cells and formalin-resistant mast cell. Arerugi. 1993;42(8):894‐899.
21.
OtsukaHInabaMFujikuraT, et al.Histochemical and functional characteristics of metachromatic cells in the nasal epithelium in allergic rhinitis: Studies of nasal scrapings and their dispersed cells. J Allergy Clin Immunol. 1995;96(4):528‐536.
22.
BaraniukJN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol. 1997;99(2):S763‐S772.
23.
JacobsonMRJuliussonSLöwhagenO, et al.Effect of topical corticosteroids on seasonal increases in epithelial eosinophils and mast cells in allergic rhinitis: A comparison of nasal brush and biopsy methods. Clin Exp Allergy. 1999;29(10):1347‐1355.
24.
HowarthPHSalageanMDokicD. Allergic rhinitis: Not purely a histamine-related disease. Allergy. 2000;55(Suppl 64):7‐16.
25.
SalibRJKumarSWilsonSJ, et al.Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis. Allergy Clin Immunol. 2004;114(4):799‐806.
26.
OtsukaHMezawaAOhnishiM, et al.Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy. 1991;21(21):115‐119.
27.
OtsukaKOtsukaHMatsuneS, et al.Decreased numbers of metachromatic cells in nasal swabs in Japanese cedar pollinosis following sublingual immunotherapy. Immun Inflamm Dis. 2020;8(3):333‐343.
28.
OtsukaKOtsukaHMatsuneS, et al.Allergen-specific subcutaneous immunotherapy for Japanese cedar pollinosis decreases the number of metachromatic cells and eosinophils in nasal swabs during the preseason and in season. Immun Inflamm Dis. 2020;8(3):258‐266.
29.
DurhamOC. The volumetric incidence of atmospheric allergens. IV. J. Allergy. 1946;17:79‐86.
30.
OkuboKKuronoYIchimuraK, et al.Japanese Society of allergology. Japanese guidelines for allergic rhinitis. Allergol Int. 2017;66(2):205‐219.
31.
YamadaTSaitoHFujiedaS. Present state of Japanese cedar pollinosis: The national affliction. J Allergy Clin Immunol. 2014;133(3):632‐639.
32.
MatsubaraASakashitaMGotoM, et al.Epidemiological survey of allergic rhinitis in Japan 2019. Nippon Jibiinnkouka Gakkai Kaiho (Tokyo). 2020;123(6):485‐490.
33.
YamanakaKYutaAKakedaM, et al.Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol. 2009;124(4):842‐845.
34.
FujimuraTYonekuraSTaniguchiY, et al.The induced regulatory T cell level, defined as the proportion of IL-10(+) Foxp3(+) cells among CD25(+) CD4(+) leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: A preliminary report. Int Arch Allergy Immunol. 2010;153(4):378‐387.
35.
BreitfeldDOhlLKremmerE, et al.Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192(11):1545‐1452.
36.
HaynesNMAllenCDCLesleyR, et al.Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1 high germinal center. J Immunol. 2007;179(8):5099‐5108.
37.
ShigeharaKKamekuraRKegamiI, et al.Circulating T follicular helper 2 cells, T follicular regulatory cells and regulatory B cells are effective biomarkers for predicting the response to house dust mite sublingual immunotherapy in patients with allergic respiratory diseases. Front Immunol. 2023;14:1284205.
38.
MuraoTKouzakiHAraiH, et al.Increase in the prevalence of follicular regulatory T cells correlates with clinical efficacy of sublingual immunotherapy with house dust mites. Int Forum Allergy Rhinol. 2024;14(1):57‐67.
39.
CollisonLWWorkmanCJKuoTT, et al.The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566‐569.
40.
ShamjiMHLayhadiJAAchkovaD, et al.Role of IL-35 in sublingual allergen immunotherapy. J Allergy Clin Immunol. 2019;143(3):1131‐1142.
41.
OtsukaHOtsukaKOkuboK. Reactivity to specific antigen of submucosa mast cells in allergic rhinitis was very low but enhanced by pretreated with stem cell factor. Am J Allergy Asthma Immunol Res. 2020;1(1):1‐6.
42.
KimY-KNakagawaNNakanoK, et al.Stem cell factor in nasal polyposis and allergic rhinitis: Increased expression by structural cells is suppressed by in vivo topical corticosteroids. J Allergy Clin Immunol. 1997;100(3):389‐399.
43.
OtsukaHKusumiTKanaiS, et al.Stem cell factor mRNA expression and production in human epithelial cells: Contribution to the accumulation of mast cells in the nasal allergy. J Allergy Clin Immunol. 1998;102(5):757‐764. doi:https://doi.org/10.1016/S0091-6749(98)70015-6
44.
AltmanMCLaiYNolinJD, et al.Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling. J Clin Invest. 2019;129(11):4979‐4991.
45.
HsiehFHSharmaPGibbonsA, et al.Human airway epithelial cell determinants of survival and functional phenotype for primary human mast cells. Proc Natl Acad Sci USA. 2005;102(40):14380‐14385.
46.
NagarkarDRPoposkiJAComeauMR, et al.Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol. 2012;130(1):225‐232.
